Amylin Pharmaceuticals' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Amylin Pharmaceuticals (AMLN)

Q1 2012 Earnings Call

April 26, 2012 8:30 am ET

Executives

Christine Everett-Zedelmayer -

Daniel M. Bradbury - Chief Executive Officer, President, Director and Member of Risk Management and Finance Committee

Mark G. Foletta - Chief Financial Officer and Senior Vice President of Finance

Vincent P. Mihalik - Chief Commercial Officer and Senior Vice President of Sales & Marketing

Christian Weyer - Senior Vice President of Research and Development

Analysts

Alethia Young

Thomas Wei - Jefferies & Company, Inc., Research Division

Thomas J. Russo - Robert W. Baird & Co. Incorporated, Research Division

Karen E. Jay - JP Morgan Chase & Co, Research Division

Unknown Analyst

Christopher Mortko

Nicholas Bishop - Cowen and Company, LLC, Research Division

Terence C. Flynn - Goldman Sachs Group Inc., Research Division

Michael G. King - Rodman & Renshaw, LLC, Research Division

David Friedman - Morgan Stanley, Research Division

Presentation

Operator

Welcome to the Amylin Pharmaceuticals Q1 2012 Earnings Call. [Operator Instructions] This conference is being recorded. If you have any objections, you may disconnect at this time. I would like to introduce your host, Christine Everett-Zedelmayer, Senior Director, Investor Relations.

Christine Everett-Zedelmayer

Good morning, and welcome to Amylin Pharmaceuticals' quarterly update conference call. We have uploaded a presentation to the Investor Relations section of our corporate website at amylin.com to accompany this conference call that provides additional background on the quarter.

Today's discussion will contain forward-looking statements that involve risks and uncertainties. These risks and uncertainties are outlined in today's press release, the website presentation and in our recent filings with the Securities and Exchange Commission. Our actual results could differ materially from what is discussed on today's call.

If you liked this article you might like

Link: I'm a Buyer of Bristol Myers in Low $30s

Eli Lilly, Verastem and the Defenders of Shareholder Value

Obamacare vs. the Stock Market

Stocks Finish Mixed; Nasdaq Extends Rally

Stephanie Link's Can Kickers -- Notes on Bristol-Myers Squibb